NSC001

Phase 2Small molecule

NNSC-Therapeutics

NSC001 is one of 5 small molecule programs targeting Mild to Moderate Alzheimer's Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mild to Moderate Alzheimer's DiseaseNot yet recruiting

Mild to Moderate Alzheimer's DiseasePhase 2

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Mild to Moderate Alzheimer's Disease

#DrugCompanyPhaseTrials

Choline Alfoscerate

Chong Kun Dang Pharmaceutical

Phase 3

1 2

Sodium Pentaborate

TTabriz University of Medical Sciences

Phase 2

1 3

NSC001

NNSC-Therapeutics

Phase 2

1 4

Neuroepo

IInternational Center for Neurological Restoration, Cuba

Phase 2

1 5

RO7126209

Roche

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mild to Moderate Alzheimer's Disease1 trial

A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease

Not yet recruiting·NNSC-Therapeutics·Phase 1/2·NCT06995573·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NSC001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NSC001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NSC001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NSC-Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNSC-Therapeutics

NSC001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mild to Moderate Alzheimer's Disease1 trial

References

Drug Info

Quick Facts

Related News